Accure develops a “Lab-in-a-Loop” platform that integrates AI protein design, patented automation systems, and a proprietary biomarker database to rapidly design and validate nanobinder and nanovesicle therapeutics, targeted to the right cells for the right patients.

 

Accure's initial technology originated from the Harvard Medical School and Massachusetts General Hospital. Together with clinical and industry partners, Accure is developing unique solutions for cancer, neurodegeneration and other complex diseases.